Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mailuoshutong is a Traditional Chinese Medicine (TCM) formulation developed by Lunan Hope Pharmaceutical Co., Ltd. It is primarily indicated for the treatment of vascular and circulatory disorders, including mixed hemorrhoids, deep vein thrombosis (DVT), and superficial thrombophlebitis. The formulation is a complex mixture of herbal and animal-derived ingredients, including *Scolopendra* (centipede), *Scorpio* (scorpion), *Hirudo* (leech), *Lumbricus* (earthworm), and *Lonicera japonica* (honeysuckle). Mailuoshutong exerts its therapeutic effects through anti-inflammatory, anti-thrombotic, and microcirculation-improving properties. It is specifically used to treat 'damp-heat stasis syndrome' in TCM, helping to reduce venous congestion, alleviate edema, and inhibit platelet aggregation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mailuoshutong.